Internal Medicine, Medical Oncology · Houston, TX
NPI
1639339153
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
2130 W Holcombe Blvd, 10th Floor
Houston, TX, 77030
Phone (713) 800-0656
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.0M
240,960 services
Medicare patients, 2024
562
Average age 74
Drug cost, 2024
$6.3M
2,353 prescriptions
Company payments, 2025
$1,237
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Yuval Raizen was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 53,040 times for 45 patients. In total Yuval Raizen billed 240,960 services in 153 codes, and Medicare paid $4.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-18.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 53,040 | 45 | $0.28 | $15K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 27,900 | 14 | $2.31 | $64K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 22,200 | 14 | $44.52 | $988K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 9,300 | 12 | $0.11 | $1,014 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 6,000 | 41 | $0.10 | $624 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,788 | 32 | $0.09 | $250 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,830 | 31 | $0.72 | $1,324 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 1,567 | 13 | $3.61 | $5,650 |
| 85025 Blood Count | Office | 1,438 | 458 | $7.55 | $11K |
| 99214 Office E&M - Established | Office | 1,214 | 460 | $89.40 | $109K |
| J9190 Injection, fluorouracil, 500 mg | Office | 1,141 | 14 | $2.36 | $2,696 |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 1,116 | 18 | $113.98 | $127K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 611 | 371 | $12.66 | $7,738 |
| 80047 Clinical Chemistry | Office | 546 | 239 | $13.38 | $7,305 |
| 96367 Intravenous Infusion, Hydration | Office | 541 | 57 | $21.12 | $11K |
By year: 2022 $3.6M for 212,677 services; 2023 $4.0M for 272,268 services; 2024 $4.0M for 240,960 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,438 | 458 | $7.55 | $11K |
| 80047 Clinical Chemistry | 546 | 239 | $13.38 | $7,305 |
| 82565 Clinical Chemistry | 50 | 37 | $5.02 | $251 |
| 36415 Venipuncture Blood Collection | 34 | 26 | $8.65 | $294 |
Medicare prescription drug claims, 2024
In 2024, the drug Yuval Raizen prescribed most often to Medicare patients was Letrozole, with 226 prescriptions and refills. In total Yuval Raizen wrote 2,353 Medicare prescriptions that cost $6.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 226 | 640 | 92 | $5,470 |
| Dexamethasone Generic | 116 | 126 | 54 | $2,077 |
| Tamoxifen Citrate Generic | 103 | 301 | 39 | $3,562 |
| Ondansetron Odt Ondansetron | 92 | 92 | 79 | $1,942 |
| Eliquis Apixaban | 89 | 117 | 28 | $67K |
| Prednisone Generic | 81 | 111 | 28 | $459 |
| Abiraterone Acetate Generic | 79 | 83 | 12 | $270K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 76 | 76 | 60 | $810 |
| Aprepitant Generic | 66 | 66 | 12 | $23K |
| Granisetron Hcl Generic | 62 | 63 | 48 | $12K |
| Famciclovir Generic | 58 | 88 | 16 | $2,693 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 55 | 55 | 18 | $2,080 |
| Loperamide Loperamide Hcl | 54 | 54 | 42 | $596 |
| Revlimid Lenalidomide | 52 | 52 | Under 11 | $849K |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 51 | 82 | 13 | $191 |
Brand drugs: - claims; generic drugs: 1,809 claims; opioid claims: 110.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Yuval Raizen $1,237 ($1,237 in general payments such as food, travel and fees) from 20 companies. The largest payer was Abbvie Inc. with $260.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 2 | $260 |
| SpringWorks Therapeutics, Inc. | 5 | $109 |
| GlaxoSmithKline, LLC. GSK | 4 | $109 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $104 |
| Daiichi Sankyo Inc. 4568.T | 4 | $99.66 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $77.99 |
| Genentech USA, Inc. ROG.SW | 3 | $66.32 |
| Pfizer Inc. PFE | 2 | $59.08 |
| Array Biopharma Inc PFE | 2 | $58.38 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $55.68 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.